UBS analyst Joshua Spector downgraded Corteva (CTVA) to Neutral from Buy with a price target of $80, down from $81. With the stock recovering near the price target Corteva’s risk/reward is more balanced, the analyst tells investors in a research note. UBS says that with the company planning to separate its Seed and Crop Chemicals business later this year, a degree of risk on execution is added, setting up the potential for negative surprises.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTVA:
- Corteva: Solid Seed Growth Offset by Spin-Related Risks and Limited Near-Term Upside, Justifying a Hold Rating
- Microsoft downgraded, Snap upgraded: Wall Street’s top analyst calls
- Corteva price target raised to $89 from $80 at RBC Capital
- Corteva price target raised to $86 from $78 at Oppenheimer
- Corteva price target raised to $85 from $77 at Wells Fargo